Insights Into Diffuse Large B-Cell Lymphoma – ASH Edition

Perspectives of community physicians from across the US on the management of diffuse large B-cell lymphoma (DLBCL), perception of various therapeutics, understanding of the current treatment data, and evolution of the treatment landscape

December 14, 2020
Purchase Report

Alexey Danilov, MD, PhD

City of Hope, Duarte, CA, US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on treatment of DLBCL was held online on December 14, 2020
  • Disease state and data presentations were developed in conjunction with Alexey Danilov, MD, PhD, from City of Hope in Duarte, CA
  • Insights on the following therapies were obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, polatuzumab vedotin

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 9 community oncologists from California, Florida, Georgia, and Wisconsin

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.